Welcome to our dedicated page for Cidara Theraptcs SEC filings (Ticker: CDTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cidara Therapeutics, Inc. (CDTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a former Nasdaq-listed biotechnology issuer. These documents include current reports on Form 8-K, financing-related filings, and other materials that describe Cidara’s clinical development plans, capital structure changes, government agreements, and its acquisition by Merck.
For investors and researchers analyzing Cidara’s business, the company’s 8-K filings are especially important. They detail key events such as the Agreement and Plan of Merger with Merck Sharp & Dohme LLC and a Merck subsidiary, the terms of the cash tender offer for all outstanding shares of common and Series A preferred stock, and the planned merger that will make Cidara a wholly owned subsidiary of Merck. These filings also outline conditions to closing, tender offer mechanics, termination fees, and other transaction terms.
Other 8-K reports describe Cidara’s clinical and regulatory progress with CD388. For example, filings explain updates to the planned Phase 3 registrational trial following an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), including expansion of the ANCHOR study population and the intention to seek biologics license application (BLA) approval based on a single Phase 3 study. Additional filings summarize positive topline results from the Phase 2b NAVIGATE trial and provide context on safety and prevention efficacy data.
Cidara’s filings also cover its Award/Contract with the Biomedical Advanced Research and Development Authority (BARDA) to support expanded manufacturing and clinical development of CD388, including base-period funding for onshoring manufacturing to the United States and potential option funding for further studies. Capital markets transactions, such as underwritten public offerings of common stock and suspension of an at-the-market (ATM) prospectus, are documented in 8-Ks that describe underwriting agreements, share issuance, and related legal opinions.
On Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that highlight the main points of each document. Users can quickly see what each 8-K, registration-related filing, or other report means for Cidara’s clinical programs, financing, and merger process. While Cidara’s common stock is expected to cease trading on the Nasdaq Global Market following completion of its merger with Merck, its historical filings remain a key resource for understanding the evolution of CD388, the Cloudbreak platform, and the corporate steps leading to the acquisition.
Cidara Therapeutics’ Chief Financial Officer reported a change in ownership of company common stock. On December 10, 2025, a transaction coded “F” involved 7,290 shares of common stock at $219.6 per share, identified as shares withheld to satisfy taxes upon RSU vesting.
Following this transaction, the officer directly owned 50,562 shares of Cidara Therapeutics common stock. This amount includes 352 shares acquired through the company’s Employee Stock Purchase Plan on November 20, 2025.
Cidara Therapeutics reported insider stock transactions by its COO & CLO. On December 10, 2025, 15,041 common shares were withheld to cover taxes on restricted stock unit vesting at $219.6 per share. The officer exercised employee stock options to purchase 3,500 shares at $16.654 and 6,459 shares at $20.2, and sold 9,959 shares at $220.077 per share. Following these transactions, the officer directly owned 25,033 common shares, including 400 acquired through the employee stock purchase plan, and held 6,207 stock options, with all share amounts adjusted for a 1-for-20 reverse stock split effective April 24, 2024.
Cidara Therapeutics’ Chief Medical Officer reported a routine insider stock transaction. On 12/10/2025, 10,332 shares of common stock were disposed of to cover taxes due on restricted stock unit vesting, as explained in the footnotes. After this tax withholding, the officer beneficially owned 21,286 common shares directly, which includes 200 shares acquired through the company’s Employee Stock Purchase Plan on November 20, 2025.
Cidara Therapeutics agreed to be acquired by Merck Sharp & Dohme via an all‑cash tender offer, followed by a merger under DGCL Section 251(h). Merck will commence the offer no later than December 4, 2025 to purchase Cidara common stock at $221.50 per share and Series A preferred at $15,505.00 per share, in cash, without interest and subject to withholding.
The offer is conditioned on more than 50% of outstanding shares (including Series A on an as‑converted basis) being tendered, and on receipt or expiration of required antitrust clearances. There is no financing condition. After the offer, Cidara will merge into a Merck subsidiary and become a wholly owned unit.
At closing, options vest and are cashed out for any in‑the‑money value; RSUs are cashed out at the common offer price; and warrants are deemed cashless exercised per their terms. Support agreements commit certain stockholders to tender and vote in favor. The agreement includes a $300,563,308 termination fee payable by Cidara in specified cases and a $462,405,090 reverse termination fee payable by Merck in certain antitrust‑related or timing scenarios, with an End Date of May 13, 2026.
Caymus Purchaser, Inc., a wholly owned subsidiary of Merck Sharp & Dohme LLC, announced plans to commence a tender offer to acquire all outstanding shares of Cidara Therapeutics, Inc. (CDTX), including its common stock and Series A Voting Convertible Preferred Stock, pursuant to an Agreement and Plan of Merger dated November 13, 2025.
The tender offer has not yet commenced. When launched, Merck and Caymus Purchaser will file a Schedule TO with an offer to purchase and related documents, and Cidara will file a Schedule 14D‑9 stating its position. Investors will be able to access these materials on SEC.gov. The filing includes forward‑looking statements and notes potential conditions and risks, including the need for a sufficient number of tendered shares and other customary closing conditions.
Cidara Therapeutics (CDTX) reported Q3 2025 results showing a larger operating loss as it advanced its lead antiviral, CD388. The company recorded no revenue and a net loss of $83.2 million, driven by $45.0 million of acquired in‑process R&D and higher R&D spending.
Liquidity strengthened following capital raises. As of September 30, cash and cash equivalents were $293.7 million, with $126.4 million in short‑term and $50.2 million in long‑term available‑for‑sale investments; restricted cash was $6.3 million. In June, the company completed an underwritten offering of 9,147,727 shares at $44.00 per share for net proceeds of $376.9 million, and earlier sold shares via ATM for $4.1 million.
Clinical progress continued. In June, the Phase 2b NAVIGATE study of CD388 met its primary and secondary endpoints across all doses. In September, Cidara initiated the Phase 3 ANCHOR trial evaluating a single 450mg subcutaneous dose for pre‑exposure prophylaxis of seasonal influenza. The company also entered a cost‑reimbursement BARDA contract on September 30. Shares outstanding were 29,335,397 at quarter‑end and 31,439,371 as of November 3, 2025.
Cidara Therapeutics entered a BARDA agreement that can total $339.2M, with an initial investment of approximately $58.1M to begin in September 2025 and run through September 2027. The initial funds will support the onshoring of CD388 manufacturing to U.S. contractors, a clinical trial to show comparability of a higher‑concentration formulation and different presentations, additional non‑clinical characterization against pandemic influenza strains, and development of protocols for expanded populations. BARDA may exercise up to nine options covering further clinical and non‑clinical work totaling up to $281.1M; Cidara may owe up to $192.2M in cost share for up to three of those options. The agreement starts on September 30, 2025, initially runs to September 29, 2027, and may extend but not beyond July 3, 2030. Either party may terminate with 60 days' notice; BARDA may terminate for cause. Some termination costs may be reimbursable by BARDA. The instrument is funded under federal contract 75A50125C00017 and supports Cidara's potential BLA path for CD388. Forward‑looking statements are included and subject to stated risks and uncertainties.
Cidara Therapeutics (CDTX) disclosed details about a clinical evaluation of CD388, specifying a 450-milligram dose versus placebo and a clearly defined primary endpoint based on laboratory-confirmed influenza, measured fever (≥ 37.2°C/99°F) and combinations of respiratory and systemic symptoms. The filing reiterates standard forward-looking statement language and points investors to the company's Quarterly Report for the period ended June 30, 2025 for additional risk factors.
The report emphasizes that outcomes and cash usage may differ from expectations and that the company does not intend to update forward-looking statements except as required by law. The filing is dated September 24, 2025 and is signed by Jeffrey Stein, Ph.D.
Cidara Therapeutics insider sale to cover RSU taxes Nicole Davarpanah, the company's Chief Medical Officer, sold 474 shares of Cidara Therapeutics common stock on 09/11/2025 to satisfy tax withholding obligations tied to vested restricted stock units. The weighted-average sale price reported is $62.8627, with transaction prices ranging from $62.86 to $63.50. After the reported sale, the reporting person beneficially owns 31,418 shares; this total includes 200 shares purchased through the company Employee Stock Purchase Plan on May 20, 2025. The Form 4 was executed by an attorney-in-fact on 09/15/2025.
FAQ
What is the current stock price of Cidara Theraptcs (CDTX)?
What is the market cap of Cidara Theraptcs (CDTX)?
